Comparision of Radiochemotherapy Applications that Committing with Two Different Chemotherapies Route in Locally Advanced Lung Cancer

Hilal Kiziltunc Ozmen¹, Orhan Sezen¹, Meryem Aktan², Burak Erdemci¹, Burcu Sağlam Alan³, Mustafa Vecdi Ertekin¹, Sinan Ezirmik⁴

ABSTRACT

Objective: This study investigated pre- and post-treatment tumor and lymph node dimension response rates and differences between side-effect profiles in patients with locally advanced inoperable nonsmall-cell lung cancer (NSCLC) receiving radiotherapy (RT) and concurrent chemotherapy (CT).

Materials and Methods: A total of 30 inoperable patients who had not previously received RT and having a mean age of 58.73±8.65 years with sufficient hematological reserves and normal hepatic and renal functions were included in the study. Those with pleural effusion, supraventricular lymph node metastasis, and N3 lymph node involvement were excluded. Group I (n=15) received a 21-day 75 mg/m² cisplatin (D1) and 15 mg/m² vinorelbine (D1, D8), whereas Group II (n=15) received 45 mg/m² paclitaxel and AUC2 carboplatin weekly. RT was administered using a linear accelerator device with the 3D conformal RT technique at 6-18 MV energy with a 1.8-2 Gy fraction for 6-7 weeks.

Results: Patients were randomized into Group I receiving RT and concurrent cisplatin–vinorelbine and Group II receiving weekly paclitaxel–carboplatin CT. Pre- and post-treatment tumor and lymph node dimensions significantly differed in both groups (p<0.001 and p<0.01, respectively). No significant change was observed in post-RT tumor and lymph node dimensions in terms of applied CT regimens (p>0.05).

Conclusion: The significant response achieved with concurrent RT and CT in groups I and II in the local advanced stage of NSCLC is important for local tumor control. Responses to treatment in the group of two arms did not differ.

Keywords: Non small cell lung cancer, chemotherapy, radiotherapy

Introduction

Cancer remains an important health problem with regard to the inconclusive nature of basic therapeutic principles and cost. As in the rest of the world, lung cancer is the most common type of cancer in Turkey with the highest mortality rate. The primary cause of lung cancer is smoking. Overall, 90% of men and 75%–80% of women with lung cancer in the USA have been identified as smokers. Nonsmall-cell histology constitutes approximately 80% of all lung cancers [1], and 25%–40% of patients with nonsmall-cell cancer (NSCLC) have advanced local Stage III disease at the time of diagnosis [2]. Majority of patients with Stage III NSCLC are not suitable for surgical resection and are generally treated with the combination of chemotherapy (CT) and radiotherapy (RT) [3]. Although CT is regarded as the standard therapeutic approach in patients with locally advanced inoperable NSCLC, the order of administration of RT and CT is still uncertain [4]. Inturn approach is largely associated with the eradication of systemic metastases, whereas better local control in patients treated with concurrent chemoradiotherapy results in better survival [4].

This study aimed to investigate differences in radiological response rates and side-effect profiles in patients with locally advanced inoperable NSCLC receiving RT and concurrently receiving cisplatin–vinorelbine and paclitaxel–carboplatin chemotherapies.

Materials and Methods

This study has been conducted with the approval of the Ethics Committee of the Ataturk University Medical School (protocol number: B.30.2.ATA.001.00/91). The inclusion criteria were as
follows: age 40-80 years, with Karnofsky performance status of ≥70%, with cytologically or histologically confirmed locally advanced NSCLC without possibility of surgical resection, without previously receiving RT, without other primary lesion, with radiologically measurable disease (posterior-anterior (PA) pulmonary x-ray or thoracic computerized tomography), with sufficient hematological reserves (Hgb≥10 g/dL, NE≥2.0, Plt≥100/mL), and with normal hepatic (serum bilirubin level=1.5×upper limit of normal (ULN), Alanine amino transferase (ALT) and Aspartate amino transferase (AST)=3×ULN) and renal (serum creatinine=1.5×ULN) functions. Patients not meeting the inclusion criteria and those with pleural effusion at the time of presentation, supracavicular lymph node metastasis, or N3 disease were excluded. One of 32 patients presenting to the radiology oncology clinic for pulmonary RT was excluded because he refused receiving CT and other one because of cardiac contraindication. Finally, the study was conducted on 30 patients.

Patients were randomized into 2 CT groups. RT was started on day 1 in the CT patients (Group I, n=15; Group II, n=15). Patients in Group I received 2 courses of CT. Group I CT consisted of 75 mg/m² cisplatin (D1) and 15 mg/m² vinorelbine (D1, D8) administered once every 21 days. Cisplatin was first dissolved in 1000 mL of 0.9% isotonic solution and administered intravenously (iv) in the form of 4-h infusion, whereas vinorelbine was dissolved in 100 mL of 0.9% isotonic solution and administered iv as 30-min infusion. Group II CT consisted of weekly 45 mg/m² paclitaxel and carboplatin AUC2. Paclitaxel was first dissolved in 1000 mL of 0.9% isotonic solution and was further administered iv as 1.5-h infusion, whereas carboplatin was dissolved in 100 mL of 0.9% isotonic solution and administered iv by 30-min infusion. RT was administered 5 days a week with a 1.8-2 Gy fraction (63.3 Gy for Group I and 61.1 Gy for Group II) for 6-7 weeks using 6-18 MV energy with a linear accelerator (Siemens-Primus 2002, Germany) (Table 1). The same RT technique was employed in both groups.

Statistical Analysis
Data analysis was performed using the The Statistical Package for the Social Sciences (SPSS) 19.0 statistical software (IBM Corp.; Armonk, NY, USA). Comparisons between independent groups were performed using the Mann–Whitney U test, whereas the Wilcoxon signed rank test was used to compare independent groups. p values of <0.05 were regarded as statistically significant.

### Table 1. Characteristics of cases receiving radiotherapy by chemotherapy regimens

| Characteristics          | Group I (C-V) (x±SD) n=15 | Group II (P-Cp) (x±SD) n=15 |
|--------------------------|---------------------------|---------------------------|
| Age (years)              | 60.8±6.0                  | 56.7±10.4                 |
| Smoking history (years)  | 36.0±9.2                  | 33.9±12.1                 |
| Length of treatment (months) | 6.5±4.1              | 8.4±8.2                   |
| RT dose (Gy)             | 63.3±2.9                  | 61.1±10.0                 |
| Initial weight (kg)      | 71.3±10.5                 | 72.0±13.0                 |
| Final weight (kg)        | 69.6±10.4                 | 70.8±12.8                 |

RT: radiotherapy; SD: standart deviation; C: cisplatin; V: Vinorelbine; P:Paclitaxel; Cp: Carboplatin

### Table 2. Changes in tumor and lymph node dimensions by chemotherapy regimen applied with radiotherapy

| LESION TYPE | CHANGE IN LESION SIZE (%) | Radiotherapy and Chemotherapy (C-V) | Radiotherapy and Chemotherapy (P-Cp) | TOTAL |
|-------------|---------------------------|-------------------------------------|-------------------------------------|-------|
|             | Number | Percentage | Number | Percentage | Number | Percentage |
| TUMOR       | 100% Decrease | 1 | 6.7 | 2 | 13.3 | 3 | 10.0 |
|             | ≥30% Decrease | 12 | 80 | 11 | 73.3 | 23 | 76.7 |
|             | ≥20% Increase | - | - | 1 | 6.7 | 1 | 3.3 |
|             | ≤30% Decrease or <20% Increase | 2 | 13.3 | 1 | 6.7 | 3 | 10.0 |
| LYMPH NODE  | 100% Decrease | - | - | 1 | 6.7 | 1 | 3.3 |
|             | ≥30% Decrease | 5 | 33.3 | 5 | 33.3 | 10 | 33.3 |
|             | ≥20% Increase | - | - | - | - | - | - |
|             | ≤30% Decrease or <20% Increase | 10 | 66.7 | 9 | 60 | 19 | 63.3 |

C: Cisplatin; V: Vinorelbine; P: Paclitaxel; Cp: Carboplatin

Results
Patients’ demographic data are shown in Table I, and changes in tumor and lymph node dimensions are shown in Table 2. The mean age of patients enrolled in the study was 58.73±8.65 years, and all were men. The most common histopathological subtype was squamous cell carcinoma in 18 patients (60%). Other histopathological subtypes were NSCLC of uncertain subtype in 7 patients (23.3%) and adenocarcinoma in 5 patients (16.6%). Smoking history was observed in 100% of the patients and in the family of 20%. The 2 groups were similar in terms of performance status, pathological distribution, and initial symptoms. CT was administered to all patients, except for one patient in Group II (mortality occurred at day 15 of treatment). Patients in Group I received a mean of 2 courses of CT concurrently with RT, whereas patients in Group II received a mean of 6 courses of chemotherapy.

Liver metastasis was observed in 1 patient in Group II, but no metastasis was determined in Group I. The follow-up period ranged between 15 days and 24 months, and response evaluation was performed based on check-ups 2 months after CT. Approximately 21% of patients survived during this follow-up period and 80% died. Hematological and nonhematological side effects were generally at tolerable levels. Esophagitis developed in 9 patients (60%) each in Group I [Grade I in 6 (66.7%) and Grade II in 3 (33.3%)] and Group II [Grade I in 5 (55.6%), Grade II in 3 (33.3%), and Grade III in I (11.1%)]. Neutropenia developed in 6 patients (40%) each in Group I [Grade I in 3 (50%) and Grade II in 3 (50%)] and Group II [Grade I in 5 (83.3%) and Grade II in 1 (16.7%)]. Grade II cutaneous reaction developed in 1 patient (13.3%) in Group I and in 2 patients (13.3%) in Group II. Nephrotoxicity developed in 1 patient (6.7%) in Group I but in none from Group II. Arrhythmia...
Various phase II studies on advanced NSCLC and paclitaxel have reported response rates of 21%-36%, and 1-year survival rates of 38%-41% [16-19]. Despite the low objective response rate of carboplatin (9%), the highest 1-year survival rates were achieved in a five-arm ECOG study comparing cisplatin combinations and analogs. A combination of carboplatin–etoposide was reported to yield the same response rates as the standard cisplatin–etoposide therapy and to cause less toxicity [20]. A ECOG study comprising 506 patients comparing a paclitaxel–cisplatin combination with standard cisplatin–etoposide therapy achieved higher response rates and longer survival with the paclitaxel–cisplatin combination [21]. It has been suggested that taxane combinations will predominate in the future and novel combinations will be available with this group of drugs [22]. Studies have shown that toxicity is generally low with the paclitaxel–carboplatin combination and bone marrow toxicity is dose-dependent and shortlived and can be easily controlled with colony-stimulating factors [23-27]. One large European–Canadian study showed that myelotoxicity decreased as paclitaxel infusion time was reduced [28]. For all these reasons, a paclitaxel–carboplatin combination with paclitaxel was administered through the 1.5-hour infusion in our study. A total response rate, both partial and complete, was 86.6% in the group receiving paclitaxel–carboplatin with RT. One patient (6.7%) was assessed as having stable disease, whereas disease progression was seen in another patient (6.7%). In terms of lymph node response, 6.7% of patients had complete response and 33.3% had partial response, whereas 60% of patients were regarded as having stable disease. Neutropenia developed in 6 patients (40%) in this group: Grade I in 5 (83.3%) and Grade II in 1 (16.7%). No myelosuppression requiring interruption or discontinuation of treatment occurred. No thrombocytopenia was also observed.

In conclusion, the significant response achieved with cisplatin–vinorelbine and paclitaxel–carboplatin chemotherapy concurrently administered with RT for the treatment of locally advanced inoperable NSCLC is significant in local tumor control. No difference was observed in the response rates. While selecting the appropriate chemotherapeutic regimen, separate evaluation should be performed for each patient, considering factors such as suitability for effect mechanisms, anticipated tolerability and side-effect profile, ease of application, length of application, and cost. Further studies comparing chemotherapeutic regimens with long postchemoradiotherapy follow-up will be useful for systemic control.

**Discussions**

Cancer is a common health problem causing significant mortality and morbidity and poses an economic burden. Its development is a complex process, in whose etiology involves genetic, environmental, and dietary factors. In clinical practice, the form with the highest morality is lung cancer; and its development is particularly associated with smoking and genetic and various environmental factors [5-7].

The only known curative treatment for Stages I and II NSCLC is surgery; <30% of all patients with NSCLC are within operable limits upon the diagnosis. The standard approach for Stage III B NSCLC is combined RT and CT. A large number of patients with NSCLC are Stages III and IV when diagnosed [8]. Although the life expectancy of patients with advanced grade NSCLC is low, various studies have shown significant improvements in the mean survival, quality of life, and performance with combined CT [9-10]. Therefore, different chemotherapeutic agents have been used for the treatment of NSCLC, and objective response rates of 8%-20% have been obtained; this has increased to 20%-30% with cisplatin-containing combinations [9, 11]. With vinorelbine alone (30 mg/m²/week), Le Chevalier et al. [12] achieved a 14% response rate, 31-week median survival, and a 30% 1-year survival rate, whereas with a combination of cisplatin (120 mg/m²) and vinorelbine (30 mg/m²/week), a 30% response rate, 40-week median survival, and a 35% 1-year survival rate were achieved [13]. Myelosuppression was reported as the primary toxicity. Grade 3–4 myelosuppression was observed in 79% of patients treated with combined cisplatin–vinorelbine therapy. In a phase III study, Depierre et al. [14] compared vinorelbine alone and a cisplatin–vinorelbine combination in 231 patients and reported improved objective response rates (16% and 43%, respectively) and time to progression of disease (10 and 20 weeks, respectively); however, no changes were observed in the length of survival (32 and 33 weeks, respectively) [15]. In our study, partial and complete response for our treatment were achieved in 86.7% of patients in the cisplatin–vinorelbine group also receiving RT. The remaining 13.3% were assessed as having stable disease, without disease progression. In terms of lymph node response, 33.3% partial response was observed and the remaining 66.7% were assessed as having stable disease. Neutropenia developed in 6 (40%) patients: Grade I in 3 (50%) and Grade II in 3 (50%). No myelosuppression requiring interruption or discontinuation of treatment was encountered.

Various phase II studies on advanced NSCLC and paclitaxel have reported response rates of 21%-36%, and 1-year survival rates of 38%-41% [16-19]. Despite the low objective response rate of carboplatin (9%), the highest 1-year survival rates were achieved in a five-arm ECOG study comparing cisplatin combinations and analogs. A combination of carboplatin–etoposide was reported to yield the same response rates as the standard cisplatin–etoposide therapy and to cause less toxicity [20]. A ECOG study comprising 506 patients comparing a paclitaxel–cisplatin combination with standard cisplatin–etoposide therapy achieved higher response rates and longer survival with the paclitaxel–cisplatin combination [21]. It has been suggested that taxane combinations will predominate in the future and novel combinations will be available with this group of drugs [22]. Studies have shown that toxicity is generally low with the paclitaxel–carboplatin combination and bone marrow toxicity is dose-dependent and shortlived and can be easily controlled with colony-stimulating factors [23-27]. One large European–Canadian study showed that myelotoxicity decreased as paclitaxel infusion time was reduced [28]. For all these reasons, a paclitaxel–carboplatin combination with paclitaxel was administered through the 1.5-hour infusion in our study. A total response rate, both partial and complete, was 86.6% in the group receiving paclitaxel–carboplatin with RT. One patient (6.7%) was assessed as having stable disease, whereas disease progression was seen in another patient (6.7%). In terms of lymph node response, 6.7% of patients had complete response and 33.3% had partial response, whereas 60% of patients were regarded as having stable disease. Neutropenia developed in 6 patients (40%) in this group: Grade I in 5 (83.3%) and Grade II in 1 (16.7%). No myelosuppression requiring interruption or discontinuation of treatment occurred. No thrombocytopenia was also observed.

In conclusion, the significant response achieved with cisplatin–vinorelbine and paclitaxel–carboplatin chemotherapy concurrently administered with RT for the treatment of locally advanced inoperable NSCLC is significant in local tumor control. No difference was observed in the response rates. While selecting the appropriate chemotherapeutic regimen, separate evaluation should be performed for each patient, considering factors such as suitability for effect mechanisms, anticipated tolerability and side-effect profile, ease of application, length of application, and cost. Further studies comparing chemotherapeutic regimens with long postchemoradiotherapy follow-up will be useful for systemic control.

**Ethics Committee Approval:** Ethics committee approval was received for this study from the ethics committee of Ataturk University Medical School (protocol number: B.302.ATA.001.00991).

**Informed Consent:** Written informed consent was obtained from the patients who participated in this study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept – H.K.O., O.S.; Design – H.K.O.; Supervision – H.K.O.; Resources – H.K.O.; Materials – H.K.O., M.A.; Data Collection and/or Processing – H.K.O., S.E., B.S.A.; Analysis and/or Interpretation – H.K.O., O.S.; Literature Search – H.K.O., M.V.E.; Writing Manuscript – H.K.O.; Critical Review – H.K.O., O.S.; Other – B.E.

**Acknowledgements:** We gratefully acknowledge Dr. Figen Sezen who helped with the study statistical evaluation.

**Conflict of Interest:** The authors have no conflicts of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**References**

1. Detterbeck FC. Diagnosis and treatment of lung cancer, in An Evidence-Based Guide for the Practicing Physician. Phyledelphia, PA, WB Sounders, 2000.

2. Bulzbruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: Prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102-10.

3. Govindan R. Management of patients with non-small cell lung cancer and poor performance status. Curr Treat Options Oncol 2003; 4: 55-9. [CrossRef]

4. Johnson DH, Turissi AT. Combined modality treatment for locally advanced, unresectable non-small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turissi AT, Minna JD, editors. Lung Cancer: Principles and Practice, 2nd ed. Philadelphia: Lippincott Williams and Wilkins 2000: 910-20.

5. Rosen RJ. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065. Ann Intern Med 2019; 170: 740. [CrossRef]

6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. [CrossRef]

7. Ginsberg RS, Vokes EE, Raben A. Non-small cell lung cancer: In: DeVita VT Sr, Hellman S, Rosenberg SA; eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997: 858-911.

8. Hsu W, Fang J, Nie J, et al. Efficacy and safety of extended use of platinum-based doublet che-
motherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine (Baltimore) 2016; 95: e4183. [CrossRef]

10. Artal Cortes A, Calera Urguizu L, Hernando Cubero J. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res 2015; 4: 191-7.

11. Grili R, Oxman AD, Julian JA. Chemotherapy for advanced Non-small Cell Lung Cancer: How much benefit is Enough? J Clin Oncol 1993; 11: 1866-72. [CrossRef]

12. Le Chevalier, R Arriagada, P Baldeyrou, et al. Inoperable Lung Epidermoid Cancer Non Metastasizing. A Phase II Trial Using Radiotherapy and Combined Chemotherapy. Bull Cancer 1985; 72: 25-9.

13. Klastersky J. VP-16 and cisplatin in the treatment of non small cell lung cancer. Semin Oncol 1985; 12: 17-20.

14. Depierre A, Chastang C, Quoix E, et al. Vinorelbine Versus Vinorelbine Plus Cisplatin in Advanced Non-Small Cell Lung Cancer: A Randomized Trial. Ann Oncol 1994; 5: 37-42. [CrossRef]

15. Gralla RJ, Kardinal CG, Otten MC, et al. Vinorelbine in combination with cisplatin or mitomycin enhancing safety, efficacy and dose intensity. Lung Cancer 1994; 11: 119. [CrossRef]

16. Gerber DE, Swanson P, Lopez-Chavez A, et al. Phase II study of olaratumab with paclitaxel/ carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer 2017; 111: 108-15. [CrossRef]

17. Soejima K. Naoki K, Ishioka K, et al. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2015; 75: 513-9. [CrossRef]

18. Rosell R, Gonzales JL, Alberola V, et al. Single agent Paclitaxel by 3-hour infusion in the treatment of NSCLC: Links Between p53 and K-ras Gene Status and chemosensitivity. Semin Oncol 1995; 22: 12-18.

19. Belani CP. Paclitaxel and Docetaxel combinations in NSCLC. Chest 2000; 117: 144-51. [CrossRef]

20. Saad AS, Ghal RR, Shawki MA. A prospective randomized controlled trial of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer. J Cancer Res Ther 2017; 13: 198-203. [CrossRef]

21. Bonomi P, Kim K, Jiang A, Johnson D. Phase III trial comparing etoposide cisplatin versus Taxol with cisplatin G-CSF versus Taxol-cisplatin in advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 1996; 15: 382.

22. Morgan KM, Fischer BS, Lee FY, et al. Gamma secretase inhibition by BMS-906024 enhances efficacy of paclitaxel in lung adenocarcinoma. Mol Cancer Ther 2017; 16: 2759-69. [CrossRef]

23. van der Burg ME, Vergote I, Onstenk W, et al. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer. Eur J Cancer 2013; 49: 1254-63. [CrossRef]

24. Scagliotti GV, Crino L, Pozzi E, et al. Phase III dose finding study of Paclitaxel and Carboplatin in advanced NSCLC. Lung Cancer 1999; 25: 39-46. [CrossRef]

25. Han BH, Xiuy QY, Wang HM, et al. A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC). Chin J Oncol 2011; 33: 854-9.

26. Belani CP, Kears CM, Zuhowsky EG, et al. Phase I trial, including phamacokinetic and pharmacodynamic correlations, of combination Paclitaxel and Carboplatin in patients with metastatic NSCLC. J Clin Oncol 1999; 17: 676-84. [CrossRef]

27. Zhao J, Zhang X, Hu K, et al. Outcomes and Toxicity of Concurrent Radiotherapy with Carboplatin/Paclitaxel Administered Every Three Weeks in Inoperable Advanced Non-Small Cell Lung Cancer: A Retrospective Study from A Single Center. Chin J Lung Cancer 2016; 19: 731-7.

28. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: hight-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66. [CrossRef]